Press releases
- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Key statistics
On Thursday, Kodiak Sciences Inc (KOD*:MEX) closed at 62.38, 0.00% above its 52-week low of 62.38, set on Oct 06, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 62.38 |
Low | 62.38 |
Bid | -- |
Offer | -- |
Previous close | 43.58 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.53m |
Free float | 49.56m |
P/E (TTM) | -- |
Market cap | 117.68m USD |
EPS (TTM) | -4.44 USD |
Data delayed at least 20 minutes, as of Oct 06 2022 12:30 BST.
More ▼